

## **Running title: Ethnic-specific metabolic profiles of GDM**

### **Unique Metabolic Profiles Associate with Gestational Diabetes and Ethnicity in Low and High-Risk Women Living in the UK**

**Authors: Harriett Fuller<sup>a</sup>, Mark Iles<sup>b,c</sup>, J. Bernadette Moore<sup>a</sup> and Michael A. Zulyniak<sup>a\*</sup>**

<sup>a</sup> Nutritional Epidemiology Group, School of Food Science and Nutrition, University of Leeds, Woodhouse Lane, Woodhouse, Leeds, LS2 9JT, UK.

<sup>b</sup> Leeds Institute of Medical Research, Worsley Building, University of Leeds, Clarendon Way, Woodhouse, Leeds, LS2 9JT, UK.

<sup>c</sup> Leeds Institute for Data Analytics, Worsley Building, University of Leeds, Woodhouse, University of Leeds, Clarendon Way, Woodhouse, Leeds, LS2 9JT, UK

\*Corresponding Author: Michael Zulyniak. Email. [m.a.zulyniak@leeds.ac.uk](mailto:m.a.zulyniak@leeds.ac.uk). Phone +44 113 343 0685

Data described in the manuscript will not be made available but can be requested through Born in Bradford (<https://borninbradford.nhs.uk>). Analytic code will be made available upon request pending approval by the research team.

### **Funding statement**

MZ is currently funded by the Wellcome Trust (217446/Z/19/Z). The Born in Bradford data reported here were supported by a Wellcome Trust infrastructure grant [101597] and the National Institute for Health Research ARC Yorkshire and Humber [NIHR200166]. Funding for the metabolomics analyses has been provided by the US National Institutes of Health [R01 DK10324], the European Research Council (ERC) under the European Union's Seventh Framework Programme [FP7/2007-2013] / ERC grant agreement no 669545 and the MRC via the MRC Integrative Epidemiology Unit Programme [MC\_UU\_00011/6]

HF: No conflicts of interest

MI: No conflicts of interest

JBM: No conflicts of interest

MAZ: No conflicts of interest

MI and MAZ designed research. HF and MAZ conducted research. MI and MAZ provided essential materials. HF performed statistical analyses. HF MI JBM and MAZ wrote the paper. MAZ has the primary responsibility for the final content. All authors read and reviewed the final manuscript.

### **Abbreviations**

ApoA1: Apolipoprotein A1

BIB: Born in Bradford

DHA: Docosahexanoic Acid

FAw3: Total Omega-3

FAw6: Total Omega-6

GDM: Gestational Diabetes Mellitus

GRM: Glycolysis Related Metabolites

HDL-C: High Density Lipoprotein Cholesterol

HD2L-C: High Density Lipoprotein-2 Cholesterol

IQR: Inter Quartile Range

LDL\_D: Diameter of Low Density Lipoprotein

LPS: Lipoprotein Particle Size

MSEP: Mean Square Error of Prediction

MFA: Monounsaturated Fatty Acids

MW: Mann-Whitney

NHS: National Health Service

PCA: Principal Component Analyses

OGTT: Oral Glucose Tolerance Test

oPLSDA: Orthogonal Partial Least Squares Discriminatory Analyses

SAC-H: High Weight South Asian Cases

SANC-H: High Weight South Asian Non-Cases

SAC-N: Healthy Weight South Asian Cases

SANC-N: Healthy Weight South Asian Non-Cases

PLSDA: Partial Least Squares Discriminatory Analyses

RMSEE: Root Mean Square Error of Prediction

ROC: Receiver Operator Curve

SA: South Asian

SE: Standard Error

SFA: Saturated Fatty Acids

sPLSDA: Sparse Partial Least Squares Discriminatory Analyses

TCA: Tricarboxylic Acid Cycle

VIP: Variable Importance in Projection

VLDL\_D: Diameter of Very Low Density Lipoprotein

WEs: White Europeans

WEC-N: Healthy Weight White European Cases

WENC-N: Healthy Weight White European Non-Cases

WEC-H: High Weight White European Cases

WENC-H: High Weight White European Non-Cases

1 **Abstract**

2 **Background:**

3 Gestational Diabetes Mellitus (GDM) is the most common global pregnancy  
4 complication; however, prevalence varies substantially between ethnicities with  
5 South Asians (SA) experiencing up to 3-times the risk of the disease compared to  
6 white Europeans (WEs). Factors driving this discrepancy are unclear, although the  
7 metabolome is of great interest as GDM is known to be characterised by metabolic  
8 dysregulation.

9 **Objective:**

10 This primary aim was to characterise and compare the metabolic profiles of GDM in  
11 SA and WE women (at < 28 weeks' gestation) from the Born in Bradford (BIB)  
12 prospective birth cohort in the UK.

13 **Methods:**

14 146 fasting serum metabolites, from 2668 pregnant WE and 2671 pregnant South  
15 Asian (SA) women (average BMI 26.2 kg/m<sup>2</sup>, average age 27.3 years) were  
16 analysed using partial least squares discriminatory analyses to characterise GDM  
17 status. Linear associations between metabolite values and post-oral glucose  
18 tolerance test measures of dysglycemia (fasting glucose and 2-hour post glucose)  
19 were also examined.

20 **Results:**

21 Seven metabolites associated with GDM status in both ethnicities (variable  
22 importance in projection (VIP)  $\geq 1$ ), while 6 additional metabolites associated with  
23 GDM only in WE women. Unique metabolic profiles were observed in healthy weight

24 women who later developed GDM, with distinct metabolite patterns identified by  
25 ethnicity and BMI status. Of the metabolite values analysed in relation to  
26 dysglycemia, lactate, histidine, apolipoprotein A1, HDL cholesterol, HDL2 cholesterol  
27 associated with decreased glucose concentration, while DHA and the diameter of  
28 very low-density lipoprotein particles (nm) associated with increased glucose  
29 concentration in WE women; while in SAs albumin alone associated with decreased  
30 glucose concentration.

### 31 **Conclusions**

32 This study shows that the metabolic risk profile for GDM differs between WE and SA  
33 women enrolled in BiB the UK. This suggests that aetiology of the disease differs  
34 between ethnic groups and that ethnic-appropriate prevention strategies may be  
35 beneficial.

36

37 **Keywords: GDM, metabolomics, ethnicity, South Asians, pregnancy, maternal**  
38 **health, PLSDA, sPLSDA, personalised nutrition**

39

40

41

42

43

44

45

46

47 **Introduction**

48 During pregnancy, there is a natural increase in catabolism to ensure sufficient  
49 energy for the foetus (1, 2). This increase is governed by maternal hormones,  
50 beginning as a mild change in insulin sensitivity and progressing through  
51 hyperinsulinemia to controlled insulin resistance by the third trimester (2-5). For most  
52 pregnancies, these changes are safe and controlled, with insulin sensitivity returning  
53 to a healthy state following pregnancy. However, for approximately one in seven  
54 pregnancies, insulin resistance exceeds normal “healthy“ levels and enters a diabetic  
55 state, putting the mother and her growing offspring in danger of short- and long-term  
56 health risks (6, 7). This pregnancy-induced state of diabetes, gestational diabetes  
57 mellitus (GDM), is a major global health concern with varying prevalence between  
58 populations.

59 In Middle Eastern, North Africa, and South Asian countries, GDM prevalence  
60 can exceed 20% of pregnancies, whereas in European countries prevalence of GDM  
61 is more commonly around 5% (5). Numerous lifestyle, biological, and genetic factors  
62 are thought to contribute to this disparity of risk (5, 8). Despite the numerous factors,  
63 diet is the mainstay of most prevention and treatment strategies because of its  
64 demonstrated efficacy for managing glucose concentrations (9-11). Nonetheless, we  
65 and others have demonstrated that the effects of dietary prevention strategies on  
66 maternal and offspring health are not generalisable across populations or ethnic  
67 groups, with dietary patterns demonstrating varied effects between ethnic groups in  
68 relation to both GDM prevention and birth weight (12-15). These data suggest that  
69 the metabolism and pathology of GDM may differ across populations, where some  
70 ethnic groups have unique metabolic profiles that make them more susceptible to

71 GDM (4, 5, 16-18). Specifically, elevated concentrations of alanine, numerous fatty  
72 acids (e.g., myristic acid, palmitic acid, palmitoleic acid) and lower amounts of  
73 glutamate, proline, and phospholipids in blood have been identified as predictors of  
74 GDM risk in early pregnancy (i.e., before 16 weeks) (4), with recent evidence  
75 demonstrating significant differences in the abundance of these metabolites between  
76 ethnic groups (19). Notably, evidence from Born in Bradford (BiB), a prospective  
77 multi-ethnic pregnancy and birth cohort, has demonstrated the need for potentially  
78 modified GDM assessment criteria for South Asian (SA) women because of  
79 increased risks of delivery complication and newborn macrosomia at significantly  
80 lower glucose thresholds, compared to white European (WE) women (20). Indeed,  
81 currently the UK's National Health System (NHS), routinely screens all women of  
82 South Asian ancestry for GDM while only high-risk WE women are screened (21).

83 As a consequence of this, the Diabetic Pregnancy Study Group called for  
84 increased research into the role of the metabolome on GDM in 2018 (22). To date,  
85 however, the metabolic drivers of GDM remain unclear with numerous discrepancies  
86 within the field, likely due to small, heterogeneous cohorts of heterogeneous cohorts of  
87 varying populations, cultures, and ancestral groups (23). Indeed, only one study has  
88 conducted an analysis of individual metabolites and GDM in an ethnic-specific  
89 fashion (1). This work investigated univariate associations between numerous  
90 metabolites in WE (n = 4072) and SA (n = 4702) women and demonstrated that  
91 concentrations of lipoproteins and cholesterol are typically higher in WE women and  
92 are stronger predictors of GDM (ie. have a higher VIP score), compared to SA  
93 women. However, metabolite profiles are heterogeneous mixtures of metabolites,  
94 many of which are strongly correlated and may depend on other metabolites to  
95 exhibit an effect. In light of this, multivariate approaches that assess all variables

96 simultaneously along with their inter-variable correlations (24) can be used to identify  
97 (i) patterns of uncorrelated metabolites that associate with GDM risk, and (ii) cardinal  
98 metabolites that independently associate with GDM risk. Therefore, this study aims  
99 to build upon existing work by applying multivariate statistical techniques within an  
100 ethnically diverse population to (i) determine underlining metabolite patterns that  
101 correlate with GDM, (ii) identify ethnic-specific metabolic drivers of GDM risk.

## 102 **Materials and Methods**

### 103 **i. Population Characteristics**

104 The BiB cohort was established to examine determinants of health from pregnancy  
105 and childhood into adulthood in an ethnically diverse region in the north of England  
106 (25). Between 2007 and 2010, BiB recruited 12,453 women (26-28 weeks' gestation,  
107 mean maternal age 27.8), collecting baseline data on 13,776 pregnancies and  
108 13,858 births, with 45% of the cohort of SA origin (25, 26). BiB aimed to recruit all  
109 mothers giving birth at the Bradford Royal Infirmary, the largest hospital within  
110 Bradford. Bradford is a northern English city with high levels of deprivation and a  
111 large SA population, the majority of which have Pakistani ancestry. All women were  
112 invited to partake in an oral glucose tolerance test (OGTT) for GDM diagnosis at  
113 approximately 26-28 weeks during their standard antenatal care. Almost all UK  
114 citizens utilize the NHS for antenatal care.

115

116 Of these, 11,480 women provided blood samples for metabolite analyses during the  
117 same visit as their OGTT. Written consent was gained from all participants and  
118 ethical approval was granted by the Bradford Research Ethics Committee  
119 (ref07/H1302/112)(25).



120 **ii. Blood Metabolite Analysis**

121 Full details of venous blood sample collection, preparation, metabolite quantification  
122 and validation have previously been described in detail (1). In brief, fasted blood  
123 samples were taken at the Bradford Royal Infirmary by trained phlebotomists,  
124 processed within 2.5 hours and stored at -80°C in the absence of freeze-thaw cycles.  
125 (27) Samples were processed using a high-throughput automated NMR platform and  
126 have previously been validated (Nightingale Health©; Helsinki, Finland). Metabolite  
127 values expressed as a percentage or ratio were excluded to minimize redundancy,  
128 resulting in a panel of 146 metabolite values expressed in absolute quantitative  
129 measures. This panel comprised measures of 97 lipoproteins, 9 amino acids, 2  
130 apolipoproteins, 9 cholesterol, 8 fatty acids, 8 glycerides and phospholipids, 4  
131 glycolysis-related metabolites, 2 ketone bodies, 3 measures of fluid balance and  
132 inflammation, and 3 measures of the mean lipoprotein particle diameter  
133 **(Supplemental S1).**

134 **iii. Participant Selection**

135 Of the 11,480 blood samples analyzed for metabolites, 54 samples were excluded  
136 because they failed one of five Nightingale© quality control measures (low glucose,  
137 high lactate, high pyruvate, low protein concentration and plasma samples). Of the  
138 11,426 available samples, ~3% of mothers were missing  $\geq 1$  metabolite values. The  
139 structure of missing metabolite data was assessed via the visualization and  
140 imputation of missing values (VIM) package within R (28) and multiple  
141 correspondence analysis (MCA). There was no evidence that the missing metabolite  
142 data occurred in a non-random pattern. It was therefore deemed appropriate to  
143 impute missing values. Optimized multiple imputation with iterative principal  
144 component analysis (PCA; 100 simulations, K-fold cross validation) based upon the

145 minimization of mean square error of prediction (MSEP) was performed using the  
146 missMDA package (29). A sensitivity analysis was performed to test the effect of  
147 mothers with higher rates of missingness ( $\geq 3\%$  missing metabolite values) on  
148 imputation. No detectable difference in imputation quality was noticed. As such, the  
149 metabolite data of all available 11,426 maternal samples were included for  
150 imputation.

151 Imputed metabolite data were combined with descriptive BiB reported  
152 characteristics, including participant's ethnicity, age moved to UK (if born abroad)  
153 GDM status, gestational age at sample collection (obtained from obstetric records),  
154 history of diabetes, age, BMI, smoking status, parity and whether they were carrying  
155 a singleton/multiple pregnancy. Length of residence was calculated by subtracting  
156 the age the mother moved to the UK from maternal age. When an individual was  
157 born within the UK, length of residency was taken to be mothers age.

158

159 All women were recruited prior to their scheduled GDM assessment (mean  
160 gestational age 26.1 weeks), and prior to the 28th week of pregnancy. GDM was  
161 diagnosed using a modified version of the World Health Organization criteria (1, 25).  
162 Using this criteria, a women was diagnosed with GDM if either their fasting glucose  
163 concentration exceed  $\geq 6.1$  mmol/L or if 2-hour post-load glucose concentrations  
164 was  $\geq 7.8$  mmol/L following a 75g oral glucose tolerance test (OGTT). The OGTT  
165 was completed in the morning following an overnight fast and involved the  
166 consumption of a standard solution over a 5-minute period containing the equivalent  
167 of 75g of anhydrous glucose (30). Following a GDM diagnosis all SA and WE  
168 mothers receive the same standardised care following a GDM diagnosis. Initially  
169 GDM management involves referral to a dietitian and the management of glucose

170 concentration through diet and increased exercise. If unsuccessful, managed by  
171 metformin or insulin injections will be prescribed. Women with GDM will also be  
172 offered additional antenatal appointments to monitor the health of both mother and  
173 baby throughout the pregnancy. Irrespective of GDM status, basic nutritional  
174 counselling is offered to all mothers as part of standard antenatal classes offered  
175 throughout pregnancy by the UK National Health Services (NHS) (31).

176

177 Ethnicity was self-reported. If ethnicity was not collected, details were obtained from  
178 primary care records along with information on parity and the number of registered  
179 births. Maternal age was recorded at pregnancy booking (ie., the first routine  
180 antenatal visit) and BMI was calculated using height measured at recruitment and  
181 maternal weight recorded at the first antenatal visit. When examined as a categorical  
182 variable, ethnic specific cut-offs were used to classify mothers into BMI groups  
183 (underweight:  $\leq 18.5 \text{ kg/m}^2$  in WE and SAs, normal/healthy weight:  $18.6\text{-}25 \text{ kg/m}^2$  in  
184 WEs or  $18.6\text{-}22.9 \text{ kg/m}^2$  in SAs, overweight:  $25\text{-}29.9 \text{ kg/m}^2$  for WE or  $23\text{-}27.4 \text{ kg/m}^2$   
185 for SA women; obese:  $> 30\text{kg/m}^2$  for WE or  $>27.5\text{kg/m}^2$  for SA women) (32). When  
186 analysed as a binary variable, women were grouped as having a 'healthy' or 'high'  
187 BMI if they were above/below the BMI cut-off for overweight status utilizing these  
188 ethnic-specific cut offs. Smoking status was self-reported at baseline and during  
189 pregnancy. Recruitment and the baseline assessment of covariates was the same in  
190 both ethnic groups. Summary statistics for each variable were presented as a mean  
191 and standard error (SE). Difference in baseline characteristics were calculated  
192 between women with and without GDM for continuous variables via a Mann-Whitney  
193 (MW) test, while differences for categorical variables were tested using Pearson's  
194 Chi-squared test.

195 Participants whose samples were collected after GDM diagnosis (28<sup>th</sup> week or later)  
196 were excluded from the analysis as well as mothers with a history of diabetes.

197 Individuals who reported being of a South Asian origin other than Pakistani (SA)  
198 were also excluded, due to the small sample size (therefore limited power) of other  
199 South Asian ancestry groups. In total, 5,339 participants, 2,671 SAs (all of Pakistani  
200 descent) and 2,688 White European (WE) women, were retained for analysis.

201 **(Figure 1)**

202

203 Ethnicity was self-reported and the homogeneity of the WE group has been  
204 confirmed in previous genetic analyses within BIB (33). 93.2% of the included WEs  
205 were born in the British Isles (i.e., the UK, Republic of Ireland, Channel Islands or  
206 Isle of Man), with the majority in England (91.4%). Of these women, 95.5% reported  
207 that both of their parents were also born in the British Isles. Within the group of WE  
208 women not born in the British Isles, 3.7% were born in Eastern Europe (Czech  
209 Republic, Poland, Slovakia) with the remaining proportion reporting 'other' or  
210 'unknown'. Within the SA population, 43.7% were born within the UK. Of the SA  
211 women born in the UK, 93% reported that their mother was born in Pakistan (87.4%)  
212 or India (5.6%) and 95% reported that their father was born in Pakistani (88.6%) or  
213 India (6.7%). A small proportion did not know their mother's (1.4%) or father's (1.3%)  
214 place of birth. Of the women born outside of the UK, the average age of immigration  
215 to the UK was 18.8 yrs (IQR 18 – 23).

216

217 **iv. Metabolite Discriminatory Analysis**

218 Partial least squares discriminatory analysis (PLSDA) is a supervised dimensionality  
219 reduction technique that uses all included variables to discriminate group data based

220 upon predefined outcome groups. Included variables are then ranked by the degree  
221 to which they explain the variance between groups (i.e., GDM vs non-GDM). These  
222 are known as variable importance in projection (VIPs), where  $VIPs \geq 1$  denote a  
223 variable with good discriminatory quality and predictive ability (34, 35).

224 PLSDA allowed an overall assessment of the predictive capacity of  
225 metabolites for GDM, in models with and without known GDM risk factors (i.e., BMI,  
226 maternal age, parity, multiple pregnancy, and smoking status), with ethnicity added  
227 to visually assess its effect on the model. Following this, both sets of PLSDA models  
228 were performed within each ethnic group. To assess bi-directionality, models  
229 predicting ethnicity were also executed within the overall population and GDM cases/  
230 non-cases separately using the same criteria as above.

231 The optimum number of components to include within the model was selected  
232 based upon the component's ability to significantly predict group membership within  
233 the training ( $pR^2Y \leq 0.05$ ) and validation ( $pQ^2Y \leq 0.05$ ) datasets (7-fold cross  
234 validation, 'nipals' algorithm). When multiple components were significantly  
235 predictive, the predictive component that best discriminated between groups (i.e.  
236 maximization of outcome variance explained,  $R^2Y$ ) with the minimal error (root mean  
237 squared error of estimation (RMSEE)) was selected. Data were pareto scaled and  
238 mean-centered prior to analysis. External validity was assessed via 7-fold cross  
239 validation. PLSDA models were performed via the 'ropls' package within R (36).  
240 When the size of the outcome groups differed by  $\geq 1\%$  the larger group was  
241 randomly sampled ( $n=20$ ) to minimize error. VIPs were mean averaged and SEs  
242 calculated across all significant iterations ( $pR^2Y \leq 0.05$ ,  $pQ^2Y \leq 0.05$ ) for each  
243 metabolite following the removal of outlier VIPs, defined as 1.5 x interquartile range  
244 of VIP values. Differences in the distribution of VIP values between both ethnicities

245 and case-status were assessed for significant iterations via a MW test; this was  
246 possible because all comparisons were tested against the same panel of metabolite  
247 measures. To assess the impact of smoking on PLSDA results, PLSDA models  
248 predicting smoking in the overall study population were also performed.

249

### 250 **iii. Post-Hoc multivariate analyses**

251 BMI is a suspected mediator along the casual pathway that links metabolism and  
252 GDM, was a significant driver of GDM within SA women and WE women. To explore  
253 this, the ethnic-specific impact of BMI on the metabolome and subsequent GDM  
254 diagnoses was investigated using sparse PLSDA (sPLSDA). sPLSDA is a  
255 supervised multivariate technique with the ability to predict group membership in  
256 multiclass problems (i.e., stratification by ethnicity, bodyweight, and GDM status) by  
257 simultaneously performing and balancing variable selection with group classification  
258 (37). Women were classified as 'healthy or 'overweight' based upon ethnic-specific  
259 cut-offs (BMI  $\geq 25\text{kg/m}^2$  for WE women and BMI  $\geq 23\text{kg/m}^2$  for SA women), which is  
260 the same approach used by the NHS (38). The analyses focussed on low-risk WE  
261 (n= 872) and low-risk SA women (n= 864) — i.e., only women (i) in their first  
262 pregnancy, (ii) that did not smoke during pregnancy, and (iii) were < 35 years of age  
263 were included. This was done to prevent these covariates from overpowering the  
264 models, and allowing the contributing roles of BMI on GDM to be more clearly  
265 appreciated within and between each ethnic group.

266

267 Metabolites selected by sPLSDA in each comparison were fed into PLSDA models  
268 (20 iterations) alongside highly correlated metabolites (Pearsons correlation  
269 coefficient  $\geq 0.9$ ) in order determine metabolite values contributing to the separation of

270 the outcome groups whilst balancing dimensionality reduction and group  
271 discrimination. PLSDA models were adjusted for maternal age (continuous), BMI  
272 (continuous), smoking status, parity and multiple pregnancy such as before.  
273 Differences in the distributions of metabolites within each group were also compared  
274 by a MW test.

### 275 **iii. Linear regression analyses for identified metabolite associations**

276 Linear regression models investigating the relationship between post- oral OGTT  
277 measures (fasting glucose and 2-hour post-OGTT) were performed on all metabolite  
278 values identified as important ( $VIP \geq 1$ ) in characterizing GDM status. Normality of  
279 glucose measures and metabolite values were assessed using histograms and Q-Q  
280 plots. Most metabolites (136/146) required normalization. Normality was most often  
281 achieved by log transformation (59 metabolite values); however, in some cases  
282 square-root and normal score transformation (NST) were implemented via the  
283 'rcompanion' package(39). All glucose measures were log normalized. Known GDM  
284 risk factors of maternal age (years), gestational age (days), parity, and smoking  
285 status during pregnancy (yes/no), were initially including in the models. When  
286 significant associations were observed between metabolite values and glucose in  
287 this exploratory analysis ( $P < 0.05$ ), BMI was added to the models (initially as a  
288 continuous and then as a binary variable utilizing ethnic-specific BMI cut-offs for  
289 overweight status) to assess the role of early pregnancy BMI as a mediator of  
290 metabolite-dysglycemia associations. Within SAs, a final additional adjustment of  
291 length of residency within the UK was made to account for any effects of  
292 acculturation.

## 293 Results

### 294 i. Population Characteristics

295 The mean age of participant was 26.7 years and had a mean BMI of 26 kg/m<sup>2</sup>. WE  
296 women were significantly older and had higher BMIs compared to SA women (**Table**  
297 **1**). Parity was significantly higher in SA women compared to WE women (P<0.001)  
298 and parity was only significantly higher in GDM cases compared to non-cases within  
299 SA women (**Table 1**). Smoking during pregnancy was significantly more common in  
300 WE women compared to SA women (25% vs 3%; P<0.001). No difference in  
301 proportion of singleton pregnancies (>97%) was observed between WE women and  
302 SA women. Alcohol intake was not assessed because it was reported by only 1% of  
303 SA women. The mean time of sample collection was 187 gestational days.

### 304 ii. Primary Analysis

#### 305 Metabolite Characterisation of GDM

306 In the 1st model, an overall analysis of the full cohort (i.e., both ethnic groups),  
307 PLSDA explained 21.7% of the variation between the GDM and non-GDM groups  
308 and confirmed maternal age and BMI as primary risk factors for GDM risk followed  
309 by parity, smoking status, and having a non-singleton pregnancy as the primary  
310 drivers of GDM (**Table 2**). In the full model, 7 metabolite values reported VIPs  $\geq 1$ ,  
311 including 4 fatty acid metabolite measures (total fatty acids, 18:2 linoleic acid, total  
312 MUFA and total SFA), and one glycolysis related metabolite (lactate) (**Figure 2**).  
313 Modelled independently, the PLSDA with only covariates explained 12.4% of the  
314 variation in GDM status and significantly predicted GDM status, whereas the model  
315 with only metabolites explained 13.5% of the variance in GDM but was non-  
316 significant. The 2<sup>nd</sup> model, which included ethnicity as a covariate, accounted for



317 26.6% of the variation between the GDM and non-GDM groups. The same 6  
318 metabolites we reported as predictors of GDM with an additional cholesterol  
319 metabolite measure (total esterified cholesterol). Notably, model 2 confirmed  
320 ethnicity (SA vs WE) as a major risk factor for GDM, after age and BMI. Modelled  
321 independently, 'ethnicity' and other covariates explained 15.2% of the variance in  
322 GDM status; therefore, the addition of metabolites into the model increased the  
323 amount of variance explained by over 11%.

324

### 325 **Ethnically-stratified analysis of metabolites characterising GDM**

326 In an ethnically stratified analysis (20 iterations), models only including metabolites  
327 accounted for a median average of 6.5% of the variation in GDM status in SA  
328 women and 5.8% of the variation in WE women in optimised models (ie.  
329 minimisation RMSEE and maximisation of  $R^2$ ) although no model comprising  
330 metabolites alone was significant. Conversely, models only including established  
331 clinical risk factors (age, BMI, parity, smoking status and multiple pregnancy) were  
332 significantly predictive ( $p$ -value  $R^2 < 0.05$ ,  $Q^2 < 0.05$ ) of GDM status and explained  
333 13.3% of the variation in SAs 12.8% of the variation in WEs. The addition of  
334 metabolites to these covariate models also resulted in the significant prediction of  
335 GDM. These models resulted in 26% of the variance in GDM status in WE women  
336 and 20% of the variance in SA women being accounted for, an increase of 13.6%  
337 and 6.8% when compared to covariate models in WE and SA respectively. Following  
338 adjustments for maternal age, parity, BMI, and smoking status, GDM could be  
339 predicted within both ethnicities. Maternal age, parity and BMI were predictors of  
340 GDM in both ethnicities ( $VIP \geq 1$ ), with BMI the most important predictor of GDM in SA  
341 women, while in WE women maternal age was most important predictor

342 **(Supplementary table 1)**. Smoking was a predictor of GDM only in WE women.  
343 After adjustment for confounders, 7 metabolite variables characterised GDM status  
344 (VIP $\geq$ 1) in both ethnicities (total fatty acids, total MUFA, total SFA, linoleic acid,  
345 glycoprotein acetyls, lactate, and diameter of VLDL) **(Figure 3, Supplementary**  
346 **table 2)**. Of these metabolites, the VIPs of three (lactate, glycoprotein acetyls, and  
347 linoleic acid) characterised GDM status comparatively well between ethnicities  
348 (VIP $\geq$ 1; MW P>0.05), whereas four metabolite measures (total fatty acids, total  
349 MUFA, total SFA, and VLDL\_D) characterised GDM in both ethnic groups, but were  
350 significantly stronger markers of GDM in WE women (VIP $\geq$ 1; MW P<0.05 between  
351 ethnicities). Additionally, alanine, glutamine, total cholesterol, total n-6 PUFA, total  
352 PUFA, and citrate were markers (VIP $\geq$ 1) of GDM status in WE women only. No  
353 markers of GDM were specific to SA women. On average, the optimised models  
354 explained 26% of the variance of GDM in WE women, and 20% of the variance in  
355 SA, women **(Supplementary table 3)**.

### 356 **Metabolites characterised by ethnicity**

357 To explore underlying metabolic profiles within each ethnic group, we identified  
358 metabolites that most strongly distinguished WE women and SA women. In a  
359 PLSDA including known GDM risk factors as covariates (maternal age, smoking  
360 status, parity, BMI, and GDM status), 12 metabolic measures VIP $\geq$ 1 in statistically  
361 significant models (models p-values  $R^2 > 0.05$  and  $Q^2 > 0.05$ ) and therefore were  
362 believed to have characterised ethnicity in GDM and non-GDM women: total fatty  
363 acids, serum cholesterol, SFA, MUFA, FAw6, esterified cholesterol, LA, LDL  
364 cholesterol, remnant cholesterol, phosphatidylcholine and total cholesterol.  
365 **(Supplementary table 4)**.

366

367 Additionally, ethnicity was characterised by 6 metabolites values exclusively in  
368 women diagnosed with GDM [i.e alanine, total fatty acids, linoleic acid (LA),  
369 glycoprotein acetyls, lactate and diameter of VLDL] whilst 5 metabolites values were  
370 exclusive in those not diagnosed with GDM [i.e., apolipoprotein A1, remnant  
371 cholesterol, docosahexanoic acid (DHA), and phosphatidylcholine]. An additional 9  
372 metabolite values [i.e., total serum cholesterol, LDL cholesterol, total esterified  
373 cholesterol, n-3 fatty acids, PUFA, MUFA, SFA, phosphatidylcholine and total  
374 cholines] were predictive of ethnicity in both GDM cases and non-cases  
375 **(Supplementary figure 1).**

#### 376 **iv. Post-Hoc Analyses**

##### 377 **Characterisation of GDM in Low-Risk Women**

378 BMI was classified as an important variable ( $VIP \geq 1$ ) in the overall analysis and in  
379 both ethnic subgroup analyses. However, a greater mean VIP ( $\pm$  SE) was observed  
380 in SA women compared to WE women ( $VIP_{SA} = 7.06 \pm 0.22$  vs.  $VIP_{WE} = 4.33 \pm 0.22$ ;  
381  $P < 0.001$ ) **(Supplementary table 1)** indicating that BMI may be a more important  
382 predictor of GDM status within WEs. Indeed, healthy weight SA women who  
383 developed GDM ( $SA_{Healthy-GDM}$ ) presented the most distinct metabolic profile  
384 (Receiver Operator Curve;  $ROC = 0.783$ ), but were most similar to healthy WE  
385 women who developed GDM ( $WE_{Healthy-GDM}$ ;  $ROC = 0.691$ ) **(Supplementary figure**  
386 **2)**. The reason for this shared and distinct pattern of metabolites in ‘healthy’ weight  
387 women who developed GDM is unclear and many hypotheses are possible. One  
388 hypothesis may be that the pattern is an artifact of their fetal programming. Adult  
389 offspring from GDM pregnancies are at increased risk of dysglycemia, diabetes, and

390 GDM that has been attributed to metabolic dysregulation, and early dysglycemia that  
391 progresses in later life (40-43).

392 Future work in established cohorts that investigate trans-generational pregnancy  
393 risks (such as Born in Bradford, Generation R, and Nutrigen) are integral to unravel  
394 the source of this unique metabolic profile which distinguishes healthy weight GDM  
395 cases of SA ancestry from non-cases, overweight SA cases, and WE cases (25, 44,  
396 45). Due to the higher proportion of underweight mothers of SA ancestry, a  
397 sensitivity analysis was performed where underweight mothers were removed  
398 ( $n_{\text{removed}} = 93$ ,  $\text{BMI} \leq 18.5 \text{ kg/m}^2$ ) to determine if their profiles were unique. No  
399 difference in the outcome was observed following the removal of these individuals.

400 Metabolites selected by sPLSDA in each comparison were fed into PLSDA  
401 models (20 iterations) alongside highly correlated metabolites (Pearsons correlation  
402 coefficient  $\geq 0.9$ ) to identify key metabolic drivers of this separation (**Supplementary**  
403 **figure 3**). Alanine, glutamine, and glycerol were important to distinguish healthy  
404 weight SA women who developed GDM (SAC-N) from all others, whereas fatty acids  
405 were important to distinguish SAC-N from other GDM cases. Interestingly, in healthy  
406 women, aromatic and branched chain amino acids distinguished GDM and non-GDM  
407 women between (but not within) ethnic groups. Glycerol distributions were  
408 significantly different in all comparisons ( $MW < 0.05$ ).

#### 409 **Characterisation of GDM in low-risk women by BMI and ethnicity**

410 Orthogonal partial least squares discriminant analysis (oPLSDA) is a supervised  
411 multivariate technique that separates variation within each predictor variables based  
412 upon its linear (correlated) and orthogonal (uncorrelated) association with the  
413 outcome variable (46, 47). This can provide better separation along fewer  
414 components when a large proportion of variance within the dataset does not directly

415 correlate with the outcome variable. Furthermore, through the creation of Shared and  
416 Unique Structure (SUS) plots it is possible to determine shared and unique factors  
417 separating the main group of interest (healthy weight SA cases, SAC-N) with the  
418 two most relevant biological comparisons (healthy weight SA non-cases, SANC-N  
419 and healthy weight WE cases, WEC-N).

420 No significant separation of the SAC-N vs SANC-N, SAC-N vs SAC-H and SAC-  
421 N vs WEC-N groups were identified via SUS plots with oPLSDA. Following the  
422 inclusion of BMI and age within the models the SAC-N group was found to separate  
423 from all other groups (**Supplementary figure 4**). BMI was the only variable found to  
424 be responsible for this separation with a high magnitude and reliability. Pyruvate, L-  
425 HDL and XL-HDL had a small impact on the separation of the SAC-N group but with  
426 a low reliability, as shown within SUS-plots.

#### 427 **Association between important metabolites and gestational dysglycemia**

428 Overall, 8 of 146 metabolite measures were associated with fasting glucose or 2-  
429 hour post glucose (**Table 3**), all of which were identified as GDM predictors via  
430 PLSDA or sPLSDA. The analysis in WE women demonstrated the greatest number  
431 of associations between metabolite and glucose measures. Six metabolites  
432 positively associated fasting glucose concentration (albumin, lactate, histidine,  
433 apolipoprotein A1, HDLC and HDL2C), while one negatively associated with fasting  
434 glucose (mean density of LDL) (**Supplementary table 5, Supplementary table 6**).  
435 Only DHA associated with 2-hr post OGTT in WEs, where a 1 mmol/L increase in  
436 DHA associated with a 0.20 mmol/L increase in 2-hour post glucose. In the analysis  
437 of SA women, only albumin was associated with dysglycemia, where higher albumin  
438 associated with lower concentration of fasting glucose and 2-hr post OGTT. In an  
439 additional analysis, length of residency within the UK was added to the fully-adjusted

440 model to evaluate the role of UK acculturation as a modifier of the association  
441 between albumin and postprandial glucose measures. In both models significant  
442 associations were identified with albumin ( $P\text{-value}_{\text{fasting}}=0.031$ ,  $\beta= -0.79$ ,  $SE=0.37$ ,  $P\text{-}$   
443  $\text{value}_{2\text{-hour}}=0.028$   $\beta=-1.75$  , $SE=0.80$ ). Length of residency was not found to be a  
444 significant variable in the model, but the magnitude of associations decreased  
445 slightly following its inclusion (**Supplementary table 5, Supplementary table 6**). In  
446 the ethnic-combined analysis, associations between albumin, lactate, and mean  
447 diameter of LDL with fasting glucose retained significance. Adjusting for BMI as a  
448 continuous or binary variable had no impact on the associations.

449

## 450 **Discussion**

451 Using a prospective birth cohort with an equal proportion of WE and SA women, we  
452 identified 7 metabolite measures that characterized GDM in both WE and SA women  
453 — 4 of which were more predictive in WE women. These results agree with the  
454 Omega cohort (78.5% non-Hispanic white; nested case-control; 46 cases, 47  
455 controls) that highlighted a distinct metabolic profile at 16-weeks' gestation  
456 (comprised of fatty acids, sugars, alcohols, amino acids and organic acids),  
457 associated with future GDM diagnosis (48). Although the metabolite patterns  
458 identified by the Omega study were not predictive, our predictive multivariate  
459 analysis (and a previous univariate analyses) (1) found similar associations between  
460 GDM and many of these metabolites (i.e., amino acids, glycolysis related  
461 metabolites, and fatty acids), and offers further evidence of ethnic-specific  
462 associations.

463           Given the overall elevated risk of GDM observed in SA women compared to  
464 WE women, even at a healthy BMI (i.e.,  $OR \approx 3$ ) (49), and the role of ethnicity in  
465 predicting GDM, in the present study, we sought to characterize distinct metabolic  
466 profiles of SA and WE women. Of the 146 metabolite values tested, 7 were important  
467 for stratifying GDM and non-GDM women in the overall population (lactate, mean  
468 density of VLDL particles, total fatty acids, total MUFAs, 18:2 linoleic acid, total SFA  
469 and esterified cholesterol). Following stratification by ethnicity, alanine, glutamine,  
470 total serum cholesterol, n-6 fatty acids, PUFAs, and citrate distinguished GDM and  
471 non-GDM in WE women whereas no metabolite values were predictive solely within  
472 SA women.

473           Although no metabolite value identified solely within WE women was  
474 associated with post-OGTT measures of glucose in *post-hoc* analyses, our evidence  
475 agrees with previous work from (i) a small case-control study (26 T2Ds vs 7 controls)  
476 that reported alanine, glutamine, and citrate to characterize GDM and controls, with  
477 citrate being a key marker of diabetics with underlying complications (e.g., CVD)  
478 (50), and (ii) a cohort study of 431 pregnant Chinese women (12-16 weeks'  
479 gestation), where alanine and glutamine were associated with GDM (51).  
480 Biologically, alanine, glutamine, and citrate are connected and could moderate  
481 dysglycemia through their interaction with the tricarboxylic acid cycle (TCA) to  
482 promote the formation of TCA intermediates, fatty acid synthesis, and modulate  
483 glucagon and insulin secretion (52, 53). Taken together, it may be that alanine and  
484 glutamine are more robust markers of dysglycemia, whereas citrate is a marker of  
485 metabolic or physiologic stress in diabetic individuals — such as pregnancy. The role  
486 of total cholesterol is uncertain as it is not convincingly associated with dysglycemia  
487 (a meta-analysis of 73 observational studies found no association)(54), suggesting

488 that associations between total cholesterol and GDM are complex and/or subject to  
489 confounding.

490 In the ethnic subgroup analyses, fatty acids were identified as the most  
491 important family (ie. VIP  $\geq 1$ ) to characterize GDM status. In WE women and SA  
492 women respectively, 75% and 50% of the fatty acids included within the metabolite  
493 panel were considered 'important' to characterize GDM within WE women.  
494 Furthermore, in SA women fatty acids constituted more than half of all metabolites  
495 with a VIP  $\geq 1$ .

496 This reflects earlier work by Taylor *et al.* [1], which identified some evidence  
497 of ethnic specific associations between fatty acids and GDM, and agrees with  
498 molecular analyses that demonstrate that fatty acids alter insulin resistance and  
499 insulin secretion during pregnancy (55, 56).

500 Furthermore, fatty acids (total MUFAs, total n-3 PUFAs, total n-6 PUFAs, total  
501 PUFAs, and DHA) were identified as key metabolic factors to distinguish healthy-  
502 weight SA and WE women who developed GDM. Interestingly, we highlighted  
503 associations between n-6 PUFA and total PUFAs with GDM that were specific to WE  
504 women. Given the equal sample sizes between groups, and that fatty acids were  
505 important to characterize ethnicity, it is suggestive of ethnic differences in PUFA  
506 metabolism (57-59) and a role in ethnic-associated GDM risk (57, 60, 61). Indeed, n6  
507 PUFA-derived eicosanoids show discriminatory qualities between type-2 diabetics  
508 and controls with good accuracy ( $R^2X = 0.824$ ,  $R^2Y = 0.995$ ,  $Q^2 = 0.779$ ) and were  
509 identified as proposed mediators of dysglycemia within a Chinese population (62).  
510 Longitudinal analyses to evaluate the association between changes in PUFA and



511 eicosanoids concentrations on dysglycemia during pregnancy are required to better  
512 understand this association.

513         The association between VLDL diameter and dysglycemia is supported by a  
514 recent hypothesis linking insulin resistance, triglyceride synthesis, and increased  
515 VLDL diameter (63, 64). Although we cannot disregard that VLDLs are sensitive to  
516 level of fasting (65) (*as our participants were subjected to prior to blood collection*),  
517 evidence also suggests that ethnic-specific genetic variants associate with ethnic-  
518 specific differences in VLDL diameter (66). Although there has been less work on the  
519 possible association between glycoprotein acetyls (a marker of systemic  
520 inflammation) and GDM, and future work is required in this area

521         Lactate was one of the strongest predictors of GDM within both groups, in  
522 agreement with evidence from a case-control study in China (n=12 GDM; n=10  
523 controls) (67) and pathway analyses that propose lactate as a regulator of insulin  
524 resistance and a marker metabolic syndrome severity (68, 69). *Post-hoc* analysis  
525 demonstrated no association between glycoprotein acetyls and glucose  
526 concentrations, while lactate and mean diameter of VLDL were associated with  
527 fasting glucose in WE women but not SA women. The multi-ethnic HAPO cohort  
528 demonstrated a similar ethnic-specific association between lactate and fasting  
529 glucose within individuals of Northern European ancestry but not minority ethnic  
530 groups (48, 70, 71).

531         Of the numerous fatty acid measures that were associated with GDM, only  
532 DHA was associated with a post-OGTT measures of glucose and only in WE  
533 women. Overall, DHA is considered a protective metabolite against insulin resistance  
534 (e.g., HOMA-IR); however, recent evidence suggests high heterogeneity (56, 72, 73).

535 As we did, researchers investigating the Camden pregnancy cohort (n=1,368)  
536 reported a significant positive linear association between DHA and HOMA-IR (0.303  
537  $\pm$  0.152 per unit DHA %; P<0.05) (56), while conversely, the DOMINO trial (n=1990  
538 pregnant women) reported no difference in 1-hr post-OGTT glucose concentrations  
539 between DHA supplemented mothers and controls (74). The reason for such  
540 discrepancies is unclear but may be that n-3 PUFAs (such as DHA) require  
541 interactions with other metabolites (e.g., Vitamin D) (75) to impart an effect,  
542 concentrations of which vary considerably between populations, seasons, and  
543 geographic region (76-78).

544 The study aimed to increase and test generalizability of results within a  
545 diverse population; however, our results may not be generalizable across other  
546 ethnic groups or geographic regions. Nonetheless, this study has four main  
547 limitations. Firstly, samples were taken at a single time point before 28 weeks  
548 gestation, therefore (i) we were unable to account for differences in fasting duration  
549 and diurnal variation; and (ii) our results are not generalizable across the full-term of  
550 pregnancy. Secondly, as with all observational studies, the effect of confounding  
551 cannot be disregarded and causality cannot be inferred. Despite this, this is the first  
552 study to use a panel of multivariate statistical techniques to characterize GDM within  
553 a large prospective cohort with an equal representation of WE women and women  
554 from a non-WE population, meaning that statistical power to measure the same  
555 effect size is comparable between groups. Thirdly, the biological validity of the  
556 identified metabolites was tested and many correlated with postprandial glucose  
557 measures; and although confounding cannot be eliminated, all models included  
558 known GDM confounders and modelling characterizing the overall metabolic  
559 differences between ethnicities were also performed to test whether differences in

560 metabolite profiles were found between ethnicities in relation to GDM status. Finally,  
561 diet is a contributor to metabolite concentrations, but comprehensive dietary data  
562 was not available for our analysis. Future work with comprehensive dietary records  
563 are needed evaluate the presence of a moderating effect of diet on metabolism and  
564 GDM risk.

## 565 **Conclusion**

566 In conclusion, this study has identified unique and shared metabolic profiles  
567 that characterize GDM in WE and SA women. Future work exploring the moderating  
568 role of lifestyle on the metabolome and the underlying biological mechanisms driving  
569 the identified associations will provide a better understanding of the etiological  
570 factors responsible for the heightened level of GDM risk experienced by SA women  
571 and shed light on improved prevention strategies

572

## 573 **Acknowledgements**

574 Born in Bradford (BiB) is only possible because of the enthusiasm and commitment  
575 of the children and parents in BiB. We are grateful to all the participants, health  
576 professionals, schools and researchers who have made Born in Bradford happen

## References

1. Taylor K, Ferreira DLS, West J, Yang T, Caputo M, Lawlor DA. Differences in Pregnancy Metabolic Profiles and Their Determinants between White European and South Asian Women: Findings from the Born in Bradford Cohort. *Metabolites*. 2019;9(9).
2. Zeng Z, Liu F, Li S. Metabolic Adaptations in Pregnancy: A Review. *Ann Nutr Metab*. 2017;70(1):59-65.
3. Egan AM, Dow ML, Vella A. A Review of the Pathophysiology and Management of Diabetes in Pregnancy. *Mayo Clin Proc*. 2020;95(12):2734-46.
4. Chen Q, Francis E, Hu G, Chen L. Metabolomic profiling of women with gestational diabetes mellitus and their offspring: Review of metabolomics studies. *J Diabetes Complications*. 2018;32(5):512-23.
5. McIntyre HD, Catalano P, Zhang C, Desoye G, Mathiesen ER, Damm P. Gestational diabetes mellitus. *Nat Rev Dis Primers*. 2019;5(1):47.
6. Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. *Diabetol Metab Syndr*. 2019;11:11.
7. Zhu Y, Zhang C. Prevalence of Gestational Diabetes and Risk of Progression to Type 2 Diabetes: a Global Perspective. *Curr Diab Rep*. 2016;16(1):7.
8. Saravanan P, Magee LA, Banerjee A, Coleman MA, Von Dadelszen P, Denison F, Farmer A, Finer S, Fox-Rushby J, Holt R, et al. Gestational diabetes: opportunities for improving maternal and child health. *The Lancet Diabetes & Endocrinology*. 2020;8(9):793-800.
9. Mijatovic-Vukas J, Capling L, Cheng S, Stamatakis E, Louie J, Cheung NW, Markovic T, Ross G, Senior A, Brand-Miller JC, et al. Associations of Diet and Physical Activity with Risk for Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Nutrients*. 2018;10(6):698.
10. American Diabetes A. 14. Management of Diabetes in Pregnancy: <em>&lt;/em>Standards of Medical Care in Diabetes—2020</em>. *Diabetes Care*. 2020;43(Supplement 1):S183.
11. NICE. Diabetes in pregnancy: management from preconception to the postnatal period 2021 [updated 16th December 2020. Available from: <https://www.nice.org.uk/guidance/ng3/chapter/Recommendations#preconception-planning-and-care>.
12. de Seymour J, Chia A, Colega M, Jones B, McKenzie E, Shirong C, Godfrey K, Kwek K, Saw S-M, Conlon C, et al. Maternal Dietary Patterns and Gestational Diabetes Mellitus in a Multi-Ethnic Asian Cohort: The GUSTO Study. *Nutrients*. 2016;8(9):574.
13. Zulyniak MA, Souza RJD, Shaikh M, Desai D, Lefebvre DL, Gupta M, Wilson J, Wahi G, Subbarao P, Becker AB, et al. Does the impact of a plant-based diet during pregnancy on birth weight differ by ethnicity ? A dietary pattern analysis from a prospective Canadian birth cohort alliance. *BMJ Open*. 2017;7.
14. Fuller H, Moore JB, Iles MM, Zulyniak MA. Ethnic-specific associations between dietary consumption and gestational diabetes mellitus incidence: a meta-analysis. *PLOS Global Public Health*. 2022.

15. Zulyniak MA, de Souza RJ, Shaikh M, Ramasundarahettige C, Tam K, William N, Desai D, Lefebvre DL, Gupta M, Subbarao P. Ethnic differences in maternal diet in pregnancy and infant eczema. *PLoS One*. 2020;15(5):e0232170.
16. Wang Q, Wurtz P, Auro K, Makinen VP, Kangas AJ, Soinen P, Tiainen M, Tynkkynen T, Jokelainen J, Santalahti K, et al. Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence. *BMC Med*. 2016;14(1):205.
17. Law KP, Zhang H. The pathogenesis and pathophysiology of gestational diabetes mellitus: Deductions from a three-part longitudinal metabolomics study in China. *Clin Chim Acta*. 2017;468:60-70.
18. McCabe CF, Perng W. Metabolomics of Diabetes in Pregnancy. *Curr Diab Rep*. 2017;17(8):57.
19. Mitro SD, Wu J, Rahman ML, Cao Y, Zhu Y, Chen Z, Chen L, Li M, Hinkle SN, Bremer AA, et al. Longitudinal Plasma Metabolomics Profile in Pregnancy—A Study in an Ethnically Diverse U.S. Pregnancy Cohort. *Nutrients*. 2021;13(9):3080.
20. Farrar D, Fairley L, Santorelli G, Tuffnell D, Sheldon TA, Wright J, van Overveld L, Lawlor DA. Association between hyperglycaemia and adverse perinatal outcomes in south Asian and white British women: analysis of data from the Born in Bradford cohort. *The Lancet Diabetes & Endocrinology*. 2015;3(10):795-804.
21. NHS. Overview Gestational Diabetes [www.NHS.co.uk](http://www.NHS.co.uk); NHS; 2019 [updated 06/08/2019. Available from: <https://www.nhs.uk/conditions/gestational-diabetes/>.
22. Schaefer-Graf U, Napoli A, Nolan CJ, Diabetic Pregnancy Study G. Diabetes in pregnancy: a new decade of challenges ahead. *Diabetologia*. 2018;61(5):1012-21.
23. Mao X, Chen X, Chen C, Zhang H, Law KP. Metabolomics in gestational diabetes. *Clin Chim Acta*. 2017;475:116-27.
24. Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, Hendriks MMWB. Reflections on univariate and multivariate analysis of metabolomics data. *Metabolomics*. 2013;10(3):361-74.
25. Wright J, Small N, Raynor P, Tuffnell D, Bhopal R, Cameron N, Fairley L, Lawlor DA, Parslow R, Petherick ES, et al. Cohort Profile: the Born in Bradford multi-ethnic family cohort study. *Int J Epidemiol*. 2013;42(4):978-91.
26. Bird PK, McEachan RRC, Mon-Williams M, Small N, West J, Whincup P, Wright J, Andrews E, Barber SE, Hill LJB, et al. Growing up in Bradford: protocol for the age 7-11 follow up of the Born in Bradford birth cohort. *BMC Public Health*. 2019;19(1):939-.
27. Taylor K, McBride N, J Goulding N, Burrows K, Mason D, Pembrey L, Yang T, Azad R, Wright J, A Lawlor D. Metabolomics datasets in the Born in Bradford cohort [version 2; peer review: 1 approved, 1 approved with reservations]. *Wellcome Open Research*. 2021;5(264).
28. Alexander Kowarik MT. Imputation with the R Package VIM. *Journal of Statistical Software*. 2016;74(7):1-16.
29. Josse J, Huisson F. missMDA: A Package for Handling Missing Values in Multivariate Data Analysis. *Journal of Statistical Software*. 2016;70(1).
30. Lawlor DA, West J, Fairley L, Nelson SM, Bhopal RS, Tuffnell D, Freeman DJ, Wright J, Whitelaw DC, Sattar N. Pregnancy glycaemia and cord-blood levels of insulin and leptin in Pakistani and white British mother-offspring pairs: findings from a prospective pregnancy cohort. *Diabetologia*. 2014;57(12):2492-500.
31. NHS. Antenatal Classes [www.NHS.co.uk](http://www.NHS.co.uk); NHS; 2021 [updated 17/03/2021. Available from: <https://www.nhs.uk/pregnancy/labour-and-birth/preparing-for-the-birth/antenatal-classes/>.

32. WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet*. 2004;363(9403):157-63.
33. Arciero E, Dogra SA, Malawsky DS, Mezzavilla M, Tsimentzoglou T, Huang QQ, Hunt KA, Mason D, Sharif SM, van Heel DA, et al. Fine-scale population structure and demographic history of British Pakistanis. *Nature Communications*. 2021;12(1):7189.
34. Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A, Mutch DM. A distinct fatty acid profile underlies the reduced inflammatory state of metabolically healthy obese individuals. *PLoS One*. 2014;9(2):e88539-e.
35. Badoud F, Lam KP, DiBattista A, Perreault M, Zulyniak MA, Cattrysse B, Stephenson S, Britz-McKibbin P, Mutch DM. Serum and Adipose Tissue Amino Acid Homeostasis in the Metabolically Healthy Obese. *Journal of Proteome Research*. 2014;13(7):3455-66.
36. Thevenot EA, Roux A, Xu Y, Ezan E, Junot C. Analysis of the Human Adult Urinary Metabolome Variations with Age, Body Mass Index, and Gender by Implementing a Comprehensive Workflow for Univariate and OPLS Statistical Analyses. *J Proteome Res*. 2015;14(8):3322-35.
37. Lê Cao K-A, Boitard S, Besse P. Sparse PLS discriminant analysis: biologically relevant feature selection and graphical displays for multiclass problems. *BMC Bioinformatics*. 2011;12(1):253.
38. NHS. BMI Healthy Weight Calculator: NHS; 2018 [updated 5/11/2018. Available from: <https://www.nhs.uk/live-well/healthy-weight/bmi-calculator/>.
39. Mangiafico S. rcompanion: Functions to Support Extension Education Program Evaluation. R package version 2.4.1. ed2021.
40. Egeland G, Meltzer SJ. Following in mother's footsteps? Mother-daughter risks for insulin resistance and cardiovascular disease 15 years after gestational diabetes. *Diabetic Medicine*. 2010;27(3):257-65.
41. Clausen TD, Mathiesen ER, Hansen T, Pedersen O, Jensen DM, Lauenborg J, Schmidt L, Damm P. Overweight and the metabolic syndrome in adult offspring of women with diet-treated gestational diabetes mellitus or type 1 diabetes. *The Journal of Clinical Endocrinology & Metabolism*. 2009;94(7):2464-70.
42. McLean M, Chipps D, Cheung NW. Mother to child transmission of diabetes mellitus: does gestational diabetes program Type 2 diabetes in the next generation? *Diabetic Medicine*. 2006;23(11):1213-5.
43. Anand SS, Gupta M, Teo KK, Schulze KM, Desai D, Abdalla N, Zulyniak M, de Souza R, Wahi G, Shaikh M. Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. *CMAJ open*. 2017;5(3):E604.
44. Jaddoe VW, Mackenbach JP, Moll HA, Steegers EA, Tiemeier H, Verhulst FC, Witteman JC, Hofman A. The Generation R Study: Design and cohort profile. *Eur J Epidemiol*. 2006;21(6):475-84.
45. de Souza RJ, Zulyniak MA, Desai D, Shaikh MR, Campbell NC, Lefebvre DL, Gupta M, Wilson J, Wahi G, Atkinson SA, et al. Harmonization of Food-Frequency Questionnaires and Dietary Pattern Analysis in 4 Ethnically Diverse Birth Cohorts. *The Journal of nutrition*. 2016;146(11):2343-50.
46. Worley B, Powers R. Multivariate Analysis in Metabolomics. *Curr Metabolomics*. 2013;1(1):92-107.
47. Blasco H, Blaszczyński J, Billaut JC, Nadal-Desbarats L, Pradat PF, Devos D, Moreau C, Andres CR, Emond P, Corcia P, et al. Comparative analysis of targeted metabolomics:

- dominance-based rough set approach versus orthogonal partial least square-discriminant analysis. *J Biomed Inform.* 2015;53:291-9.
48. Enquobahrie DA, Denis M, Tadesse MG, Gelaye B, Ressom HW, Williams MA. Maternal Early Pregnancy Serum Metabolites and Risk of Gestational Diabetes Mellitus. *J Clin Endocrinol Metab.* 2015;100(11):4348-56.
49. Makgoba M, Savvidou M, Steer P. An analysis of the interrelationship between maternal age, body mass index and racial origin in the development of gestational diabetes mellitus. *BJOG: An International Journal of Obstetrics & Gynaecology.* 2012;119(3):276-82.
50. Del Coco L, Vergara D, De Matteis S, Mensa E, Sabbatinelli J, Prattichizzo F, Bonfigli AR, Storci G, Bravaccini S, Pirini F, et al. NMR-Based Metabolomic Approach Tracks Potential Serum Biomarkers of Disease Progression in Patients with Type 2 Diabetes Mellitus. *J Clin Med.* 2019;8(5).
51. Jiang R, Wu S, Fang C, Wang C, Yang Y, Liu C, Hu J, Huang Y. Amino acids levels in early pregnancy predict subsequent gestational diabetes. *J Diabetes.* 2020;12(7):503-11.
52. Newsholme P, Brennan L, Rubi B, Maechler P. New insights into amino acid metabolism, beta-cell function and diabetes. *Clin Sci (Lond).* 2005;108(3):185-94.
53. Haber EP, Procopio J, Carvalho CR, Carpinelli AR, Newsholme P, Curi R. New insights into fatty acid modulation of pancreatic beta-cell function. *Int Rev Cytol.* 2006;248:1-41.
54. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. *BJOG.* 2015;122(5):643-51.
55. Villafan-Bernal JR, Acevedo-Alba M, Reyes-Pavon R, Diaz-Parra GA, Lip-Sosa DL, Vazquez-Delfin HI, Hernandez-Muñoz M, Bravo-Aguirre DE, Figueras F, Martinez-Portilla RJ. Plasma Levels of Free Fatty Acids in Women with Gestational Diabetes and Its Intrinsic and Extrinsic Determinants: Systematic Review and Meta-Analysis. *J Diabetes Res.* 2019;2019:7098470-.
56. Chen X, Stein TP, Steer RA, Scholl TO. Individual free fatty acids have unique associations with inflammatory biomarkers, insulin resistance and insulin secretion in healthy and gestational diabetic pregnant women. *BMJ Open Diabetes Res Care.* 2019;7(1):e000632.
57. Gray RG, Kousta E, McCarthy MI, Godsland IF, Venkatesan S, Anyaoku V, Johnston DG. Ethnic variation in the activity of lipid desaturases and their relationships with cardiovascular risk factors in control women and an at-risk group with previous gestational diabetes mellitus: a cross-sectional study. *Lipids Health Dis.* 2013;12:25-.
58. Benedetti S, Al-Tannak NF, Alzharani M, Moir HJ, Stensel DJ, Thackray AE, Naughton DP, Dorak MT, Spendiff O, Hill N. Plasma free fatty acids metabolic profile with LC-MS and appetite-related hormones in South Asian and White European men in relation to adiposity, physical activity and cardiorespiratory fitness: a cross-sectional study. *Metabolites.* 2019;9(4):71.
59. Ralston JC, Zulyniak MA, Nielsen DE, Clarke S, Badawi A, El-Sohemy A, Ma DW, Mutch DM. Ethnic-and sex-specific associations between plasma fatty acids and markers of insulin resistance in healthy young adults. *Nutrition & metabolism.* 2013;10(1):42.
60. Yuen L, Wong VW, Simmons D, Simmons D. Ethnic Disparities in Gestational Diabetes. *Current Diabetes Report.* 2018;18(68).
61. Cheung NW. The influence of ethnicity on the development of type 2 diabetes mellitus in women with gestational diabetes: a prospective study and review of the literature. *ISRN endocrinology.* 2012;2012.

62. Xia F, He C, Ren M, Xu F-G, Wan J-B. Quantitative profiling of eicosanoids derived from n-6 and n-3 polyunsaturated fatty acids by twin derivatization strategy combined with LC-MS/MS in patients with type 2 diabetes mellitus. *Analytica Chimica Acta*. 2020;1120:24-35.
63. Zhao H, Li H, Chung ACK, Xiang L, Li X, Zheng Y, Luan H, Zhu L, Liu W, Peng Y, et al. Large-Scale Longitudinal Metabolomics Study Reveals Different Trimester-Specific Alterations of Metabolites in Relation to Gestational Diabetes Mellitus. *J Proteome Res*. 2019;18(1):292-300.
64. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. *Diabetes Care*. 2004;27(6):1496-504.
65. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. *Journal of the American College of Cardiology*. 2017;70(13):1637-46.
66. Frazier-Wood AC, Manichaikul A, Aslibekyan S, Borecki IB, Goff DC, Hopkins PN, Lai C-Q, Ordovas JM, Post WS, Rich SS, et al. Genetic variants associated with VLDL, LDL and HDL particle size differ with race/ethnicity. *Human Genetics*. 2013;132(4):405-13.
67. Liu T, Li J, Xu F, Wang M, Ding S, Xu H, Dong F. Comprehensive analysis of serum metabolites in gestational diabetes mellitus by UPLC/Q-TOF-MS. *Anal Bioanal Chem*. 2016;408(4):1125-35.
68. Wu Y, Dong Y, Atefi M, Liu Y, Elshimali Y, Vadgama JV. Lactate, a Neglected Factor for Diabetes and Cancer Interaction. *Mediators Inflamm*. 2016;2016:6456018.
69. Jones TE, Pories WJ, Houmard JA, Tanner CJ, Zheng D, Zou K, Coen PM, Goodpaster BH, Kraus WE, Dohm GL. Plasma lactate as a marker of metabolic health: Implications of elevated lactate for impairment of aerobic metabolism in the metabolic syndrome. *Surgery*. 2019;166(5):861-6.
70. Jacob S, Nodzinski M, Reisetter AC, Bain JR, Muehlbauer MJ, Stevens RD, Ilkayeva OR, Lowe LP, Metzger BE, Newgard CB, et al. Targeted Metabolomics Demonstrates Distinct and Overlapping Maternal Metabolites Associated With BMI, Glucose, and Insulin Sensitivity During Pregnancy Across Four Ancestry Groups. *Diabetes care*. 2017;40(7):911-9.
71. Chen YD VB, Reaven GM. Plasma lactate concentration in obesity and type 2 diabetes. *Diabetes & Metabolism*. 1993;19(4).
72. Zhu Y, Li M, Rahman ML, Hinkle SN, Wu J, Weir NL, Lin Y, Yang H, Tsai MY, Ferrara A, et al. Plasma phospholipid n-3 and n-6 polyunsaturated fatty acids in relation to cardiometabolic markers and gestational diabetes: A longitudinal study within the prospective NICHD Fetal Growth Studies. *PLoS Med*. 2019;16(9):e1002910.
73. Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L, Group P. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2019;366:l4697.
74. Zhou SJ, Yelland L, McPhee AJ, Quinlivan J, Gibson RA, Makrides M. Fish-oil supplementation in pregnancy does not reduce the risk of gestational diabetes or preeclampsia. *Am J Clin Nutr*. 2012;95(6):1378-84.
75. Jamilian M, Samimi M, Ebrahimi FA, Hashemi T, Taghizadeh M, Razavi M, Sanami M, Asemi Z. The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. *J Clin Lipidol*. 2017;11(2):459-68.



76. Darling AL, Hart KH, Macdonald HM, Horton K, Kang'ombe AR, Berry JL, Lanham-New SA. Vitamin D deficiency in UK South Asian Women of childbearing age: a comparative longitudinal investigation with UK Caucasian women. *Osteoporos Int.* 2013;24(2):477-88.
77. Sedhain A, Bhattarai GR, Yadav SR, Pandey BR, Pant TP. Geographic and Seasonal Variation of Vitamin D: A Retrospective Study in Two Centers of Nepal. *J Nepal Health Res Counc.* 2020;18(1):103-7.
78. Lagunova Z, Porojnicu AC, Lindberg F, Hexeberg S, Moan J. The dependency of vitamin D status on body mass index, gender, age and season. *Anticancer Res.* 2009;29(9):3713-20.

**Table 1: Population Characteristics at < 28 weeks' gestation (mean gestational age 26.7 weeks) from the Born in Bradford**

	Overall	White European				South Asian				White European vs South Asian P-values		
	Total (n=5339)	Total (n=2668)	GDM (n=128)	Non-GDM (n=2540)	P-value	Total (n=2,671)	GDM (n=286)	Non-GDM (n=2385)	P-value	Overall (n=5339)	GDM (n=414)	Non-GDM (n=4925)
<b>Age (years)</b>	27.3 (0.08)	26.7 (0.1)	30 (0.5)	26.5 (0.1)	< 0.001	25.7 (0.1)	30.6 (0.3)	27.6 (0.1)	< 0.001	< 0.001	0.29	< 0.001
<b>Mothers weight at baseline assessment (kg)</b>	68.8 (0.2)	72.0 (0.3)	76.8 (1.6)	71.8 (0.3)	0.002	65.5 (0.3)	72.3 (0.9)	64.7 (0.3)	< 0.001	< 0.001	0.03	< 0.001
<b>Mothers' height (cm)</b>	162 (0.09)	164.3 (0.1)	163.8 (0.5)	164.3 (0.1)	0.47	159.7 (0.1)	158.1 (0.3)	159.9 (0.1)	< 0.001	< 0.001	< 0.001	< 0.001
<b>BMI<sup>1</sup></b>												
<i>mean (kg/m<sup>2</sup>)</i>	26.2 (0.08)	26.7 (0.1)	28.5 (0.5)	26.6 (0.1)	< 0.001	25.7 (0.1)	28.9 (0.4)	25.3 (0.1)	< 0.001	< 0.001	0.49	< 0.001
<i>underweight or normal</i>	2198 (41.2)	1254 (47)	47 (36.7%)	1207 (47.5%)	0.02	944 (35.3)	46 (16.1)	898 (37.7)	< 0.001	< 0.001	< 0.001	< 0.001
<i>overweight or obese</i>	3141 (58.8)	1414 (53)	81 (63.3%)	1333 (52.5%)		1727 (64.7)	240 (83.9)	1487 (62.3)				
<b>Parity</b>					0.47				< 0.001	< 0.001	< 0.001	< 0.001
0	2311 (43.2)	1394 (52.2)	73 (57)	1321 (52)		917 (34.3)	82 (28.7)	835 (36.5)				
1	1508 (28.2)	813 (30)	39 (30.5)	774 (30.5)		695 (26)	49 (17.1)	646 (28.3)				
2	813 (15.2)	293 (11)	11 (8.6)	282 (11.1)		520 (19.5)	57 (19.9)	463 (20.3)				
≥ 3	707 (13.2)	168 (6.3)	5 (3.9)	163 (10.4)		539 (20.2)	98 (34.3)	441 (14.9)				
<b>Singleton pregnancy (%)</b>	5274 (98.8)	2634 (98.7)	123 (96.1)	2511 (98.9)	0.01	2640 (98.8)	280 (97.9)	2360 (99)	0.12	0.70	0.29	0.75
<b>Smoked during pregnancy (%)</b>	958 (17.9)	870 (32.6)	25 (19.5)	845 (33.3)	0.001	88 (3.3)	12 (4.2)	76 (3.2)	0.37	< 0.001	< 0.001	< 0.001

<sup>1</sup> Summary table of population characteristics, expressed as a mean (SE) for continuous variables and counts (%) for categorical variables. Differences between women with and without GDM for continuous variables were tested using a Mann-Whitney test, while differences for categorical variables were tested using Pearson's Chi-squared test.

(BiB) cohort.<sup>2</sup>

---

<sup>2</sup> Body Mass Index (BMI) cut-offs: underweight,  $\leq 18.5 \text{ kg/m}^2$  in WE and SAs; normal weight,  $18.6\text{-}25 \text{ kg/m}^2$  in WEs or  $18.6\text{-}22.9 \text{ kg/m}^2$  in SAs; overweight,  $25\text{-}29.9 \text{ kg/m}^2$  for WE or  $23\text{-}27.4 \text{ kg/m}^2$  for SA women; obese,  $\geq 30 \text{ kg/m}^2$  for WE or  $\geq 27.5 \text{ kg/m}^2$  for SA women. SA, South Asian; WE, white European.

**Table 2: Key metabolite measures (VIP  $\geq 1$ ) that discriminate women diagnosed as GDM from non-GDM women in Partial Least Squares Discriminatory Analysis (PLSDA).<sup>1</sup>**

Variable	Model 1	Model 2
Age	6.4 (0.03)	5.9 (0.03)
BMI	5.4 (0.04)	5.1 (0.02)
Ethnicity	-	2.9 (0.02)
Parity	2.4 (0.01)	2.3 (0.01)
Smoking Status	1.9 (0.02)	1.7 (0.01)
Multiple Pregnancy	1.5 (0.01)	1.3 (0.009)
Lactate	1.5 (0.01)	1.2 (0.008)
VLDL_D	1.3 (0.01)	1.3 (0.01)
Total Fatty Acids	1.2 (0.01)	1.5 (0.01)
Total MUFA	1.2 (0.001)	1.2 (0.008)
18:2 Linoleic Acid	1.1 (0.01)	1.1 (0.004)
Total SFA	1.1 (0.01)	1.2 (0.007)
Esterified Cholesterol	-	1.0 (0.008)

<sup>1</sup> Variables of Importance in Projection (VIPs) scores [mean and (standard error)] across 20 PLSDA iterations discriminating between GDM (n=414) and non-GDM women (n=414). Model 1: Includes all metabolite measures plus BMI (continuous), maternal age (years), smoking status, parity and multiple pregnancy status. Model 2: Model 1 + ethnicity. GDM, Gestational Diabetes Mellitus; MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; VLDL\_D, mean diameter of very-low density lipoproteins.

**Table 3: Metabolite measures associated with dysglycemia in South Asian and white European pregnant women before 28 weeks' gestation (mean gestational age 26.7 weeks)<sup>1</sup>**

<b>Dysglycemia</b> (mmol/L)	<b>Combined analyses of South Asian and White Europeans</b> (n=5538)	<b>South Asian</b> (n=2671)	<b>White European</b> (n=2267)
<b>Fasting glucose</b>	Albumin (-) <sup>2</sup> Lactate (-) LDL_D (+)		Lactate (-) Histidine (-) ApoA1 (-) HDL-C (-) HDL2-C (-) LDL_D (+)
<b>2-hour post glucose</b>		Albumin (-)	DHA (+)

<sup>1</sup> Multivariable linear regression analysis was undertaken in the overall population of pregnant women of 2671 South Asians and 2667 White Europeans. Metabolites associated ( $P < 0.05$ ) with measures of fasting glucose or 2-hr post oral glucose tolerance test (OGTT) in the overall population or in ethnic-specific analyses are presented. All models included maternal age (years), gestational age (days), parity, BMI (continuous), and smoking status during pregnancy. No differences in association were identified when BMI was included within the model as a categorical variable.

<sup>2</sup> Direction of associations are presented in brackets — i.e. positive (+) or negative (-). ApoA1, Apolipoprotein A1; DHA, Docosahexaenoic acid; HDL-C, High-density lipoprotein cholesterol; HDL2-C, High-density lipoprotein-2 cholesterol; LDL\_D, mean diameter of low-density lipoprotein.

**Figure 1: Flow chart of study participants from the Born in Bradford (BiB) cohort included within this study.**

**Figure 2: Circular bar plot identifying key metabolites ( $VIP \geq 1$ ) that distinguished 414 women with gestational diabetes mellitus (GDM) from 414 women without GDM.**

Mean average VIP scores across 20 PLSDA model iterations ( $n_{\text{cases}} = 414$ ). Bars represent standard errors (SEs). The PLSDA included maternal age (years), BMI (continuous), smoking status, parity, and multiple pregnancy status, and ethnicity. Red line denotes VIP cut-off of 1. Units mmol/L unless stated. GRM, Glycolysis Related Metabolites; LPS, Lipoprotein Particle Size; MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; VLDL\_D, mean diameter of very-low density lipoproteins.

**Figure 3: Circular bar plot of ethnically stratified analyses identifying key metabolites ( $VIP \geq 1$ ) that distinguished GDM women from non GDM women in South Asians ( $n_{\text{cases}}=286$ ) and white Europeans ( $n_{\text{cases}}=128$ ).**

Mean average VIP scores across 20 PLSDA model iterations ( $n_{\text{casesSA}} = 286$ ,  $n_{\text{casesWE}}=128$ ). Bars represent standard errors (SEs). The PLSDA was run separately for SA (blue) and WE (red) women and included maternal age (years), BMI (continuous), smoking status, parity, and multiple pregnancy status. Red circular line denotes VIP cut-off of 1. No lipoproteins demonstrated a  $VIP > 1$  and were not included in the figure to preserve space. Units mmol/L unless stated. 18.2 LA, 18.2 Linoleic acid; GRM, Glycolysis Related Metabolites; LPS, Lipoprotein Particle Size;

MUFA, total monounsaturated fatty acids; SFA, total saturated fatty acids; Tot FA, Total fatty acids; VLDL\_D, mean diameter of very-low density lipoproteins.

11,480 samples from Born in Bradford (BiB)

11,426 samples for imputation

7,690 samples with qualitative BiB data

6,446 samples before 28<sup>th</sup> week with no history of diabetes

5,339 samples with details of Maternal age, BMI, smoking status, multiple pregnancy and parity

Failed Nightingale ©  
quality control test  
N= 54





